PLRS: a flexible tool for the joint analysis of DNA copy number and mRNA expression data

Department of Mathematics, VU University, De Boelelaan 1081a, 1081HV Amsterdam, The Netherlands.
Bioinformatics (Impact Factor: 4.62). 02/2013; 29(8). DOI: 10.1093/bioinformatics/btt082
Source: PubMed

ABSTRACT DNA copy number and mRNA expression are commonly used data types in cancer studies. Available software for integrative analysis arbitrarily fixes the parametric form of the association between the two molecular levels and hence offers no opportunities for modeling it. We present a new tool for flexible modeling of this association. PLRS employs a wide class of interpretable models including popular ones and incorporates prior biological knowledge. It is capable to identify the gene-specific type of relationship between gene copy number and mRNA expression. Moreover, it tests the strength of the association and provides confidence intervals. We illustrate PLRS using glioblastoma data from The Cancer Genome Atlas (TCGA). AVAILABILITY: PLRS is implemented as an R package and available from Bioconductor (as of version 2.12; Additional code for parallel computations is available as Supplementary Material. CONTACT:

  • [Show abstract] [Hide abstract]
    ABSTRACT: Combined analyses of molecular data, such as DNA copy-number alteration, mRNA and protein expression, point to biological functions and molecular pathways being deregulated in multiple cancers. Genomic, metabolomic and clinical data from various solid cancers and model systems are emerging and can be used to identify novel patient subgroups for tailored therapy and monitoring. The integrative genomics methodologies that are used to interpret these data require expertise in different disciplines, such as biology, medicine, mathematics, statistics and bioinformatics, and they can seem daunting. The objectives, methods and computational tools of integrative genomics that are available to date are reviewed here, as is their implementation in cancer research.
    Nature Reviews Cancer 04/2014; 14(5):299-313. DOI:10.1038/nrc3721 · 29.54 Impact Factor